



Atty Docket No.: JHV-050.01

Inventor: Tzyy-Chou Wu et al.
Application No.: 10/555,669-Conf. #9879 Filing Date: May 5, 2004
Title: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

Documents Filed:

Response to Notification of Missing Requirements (2 pages in dupl.)
Copy of Notification of Missing Requirements (3 pages)
Petition for Four Month Extension of Time Under 37 CFR 1.136(a) (1 page in dupl.)
Paper copy of Sequence Listing (17 pages)
CRF diskette of Sequence Listing (1 disk)
Statement to Support Sequence Listing submission (1 page)
Preliminary Amendment (3 pages)
Executed Declaration (1 page)
Executed Powers of Attorney (2 pages)
Notification of Change of Attorney Docket Number (1 page)

RECEIVED

Date: MAR 29 2007
PATENT DEPT
DOCKETING

Via: First Class Mail
Sender's Initials: JYA/dmn

IAP6 Rec'd PCT/PTO 22 MAR 2007

Atty Docket No.: JHV-050.01

Inventor: Tzyy-Chou Wu et al.
Application No.: 10/555,669-Conf. #9879 Filing Date: May 5, 2004
Title: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

Documents Filed:

Response to Notification of Missing Requirements (2 pages in dupl.)
Copy of Notification of Missing Requirements (3 pages)
Petition for Four Month Extension of Time Under 37 CFR 1.136(a) (1 page in dupl.)
Paper copy of Sequence Listing (17 pages)
CRF diskette of Sequence Listing (1 disk)
Statement to Support Sequence Listing submission (1 page)
Preliminary Amendment (3 pages)
Executed Declaration (1 page)
Executed Powers of Attorney (2 pages)
Notification of Change of Attorney Docket Number (1 page)

Via: First Class Mail
Sender's Initials: JYA/dmn

Date: March 19, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouo *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barreto

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed on September 19, 2006, in the above-referenced application.

Enclosed is a copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); a Petition for a Four-Month Extension of Time; a paper copy of the Sequence Listing; a Computer Readable Form of the Sequence Listing (CRF); a Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 CFR §§1.821-1.825; a Preliminary Amendment; Declaration signed by Inventors Wu and Hung; and Powers of Attorney signed by Inventors Wu and Hung.

Please charge the surcharge for a small entity (\$65.00) to our Deposit Account No. 06-1448, Reference JHV-050.01. A copy of this Response is enclosed.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448, Reference JHV-050.01**.

Respectfully Submitted,

Date: March 19, 2007

Customer No: 25181

Patent Group

Foley Hoag LLP

155 Seaport Blvd.

Boston, MA 02210-2600

Janann Ali

Janann Y. Ali, Ph.D.

Reg. No. 54,958

Agent for Applicants

Tel. (617) 832-1000

Fax. (617) 832-7000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chou et al.

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barreto

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed on September 19, 2006, in the above-referenced application.

Enclosed is a copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); a Petition for a Four-Month Extension of Time; a paper copy of the Sequence Listing; a Computer Readable Form of the Sequence Listing (CRF); a Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 CFR §§1.821-1.825; a Preliminary Amendment; Declaration signed by Inventors Wu and Hung; and Powers of Attorney signed by Inventors Wu and Hung.

Please charge the surcharge for a small entity (\$65.00) to our Deposit Account No. 06-1448, Reference JHV-050.01. A copy of this Response is enclosed.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448, Reference JHV-050.01**.

Respectfully Submitted,

Date: March 19, 2007

Customer No: 25181

Patent Group

Foley Hoag LLP

155 Seaport Blvd.

Boston, MA 02210-2600

Janann Ali

Janann Y. Ali, Ph.D.

Reg. No. 54,958

Agent for Applicants

Tel. (617) 832-1000

Fax. (617) 832-7000

S2L

JHU-18



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/555,669	Tzy-Chou Wu	26148.1180
INTERNATIONAL APPLICATION NO.		
PCT/US04/13756		
LA. FILING DATE PRIORITY DATE		
DUE: 11/19/07- w/2 mo cat 05/05/2004 05/05/2003		
FINAL: 4/19/07		
CONFIRMATION NO. 9879		
371 FORMALITIES LETTER		
 OC000000020495147		

Date Mailed: 09/19/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 11/07/2005
- Copy of the International Search Report filed on 11/07/2005
- Preliminary Amendments filed on 11/07/2005
- Information Disclosure Statements filed on 11/07/2005
- U.S. Basic National Fees filed on 11/07/2005
- Priority Documents filed on 11/07/2005



The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$65 for a Small Entity:

- \$65 Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

JOHN L ANDERSON

Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/555,669	PCT/US04/13756	26148.1180


FORM PCT/DO/EO/905 (371 Formalities Notice)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2006 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		Docket Number (Optional) JHV-050.01		
Application Number	10/555,669-Conf. #9879	Filed May 5, 2004		
For ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN				
Art Unit	N/A	Examiner Not Yet Assigned		
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.				
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):				
<input type="checkbox"/>	One month (37 CFR 1.17(a)(1))	Fee \$120	Small Entity Fee \$60	\$ _____
<input type="checkbox"/>	Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$ _____
<input type="checkbox"/>	Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ _____
<input checked="" type="checkbox"/>	Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$ 795.00
<input type="checkbox"/>	Five months (37 CFR 1.17(a)(5))	\$2160	\$1080	\$ _____
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> A check in the amount of the fee is enclosed. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>06-1448</u> , <u>Ref: JHV-050.01</u> . I have enclosed a duplicate copy of this sheet.				
I am the <input type="checkbox"/> applicant/inventor. <input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). <input checked="" type="checkbox"/> attorney or agent of record. Registration Number <u>54,958</u> <input type="checkbox"/> attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____.				
 <u>Janann Y. Ali</u> Typed or printed name			<u>March 19, 2007</u> Date <u>(617) 832-1000</u> Telephone Number	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.				
<input checked="" type="checkbox"/> Total of <u>2</u> forms are submitted.				

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19, 2007


Signature:  (John Barretto)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2006 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		Docket Number (Optional) JHV-050.01																		
Application Number	10/555,669-Conf. #9879	Filed May 5, 2004																		
For ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN																				
Art Unit	N/A	Examiner Not Yet Assigned																		
<p>This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.</p> <p>The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):</p> <table> <thead> <tr> <th></th> <th>Fee</th> <th>Small Entity Fee</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> One month (37 CFR 1.17(a)(1))</td> <td>\$120</td> <td>\$60</td> </tr> <tr> <td><input type="checkbox"/> Two months (37 CFR 1.17(a)(2))</td> <td>\$450</td> <td>\$225</td> </tr> <tr> <td><input type="checkbox"/> Three months (37 CFR 1.17(a)(3))</td> <td>\$1020</td> <td>\$510</td> </tr> <tr> <td><input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))</td> <td>\$1590</td> <td>\$795</td> </tr> <tr> <td><input type="checkbox"/> Five months (37 CFR 1.17(a)(5))</td> <td>\$2160</td> <td>\$1080</td> </tr> </tbody> </table> <p> <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> A check in the amount of the fee is enclosed. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>06-1446</u>, <u>Ref. JHV-050.01</u>. I have enclosed a duplicate copy of this sheet. </p>				Fee	Small Entity Fee	<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60	<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225	<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510	<input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795	<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080
	Fee	Small Entity Fee																		
<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60																		
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225																		
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510																		
<input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795																		
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080																		
I am the <input type="checkbox"/> applicant/inventor. <input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). <input checked="" type="checkbox"/> attorney or agent of record. Registration Number <u>54,958</u> <input type="checkbox"/> attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____.		<u>March 19, 2007</u> <u>Signature</u> <u>Janann Y. Ali</u> <u>Typed or printed name</u>																		
		<u>(617) 832-1000</u> <u>Telephone Number</u>																		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.																				
<input checked="" type="checkbox"/> Total of <u>2</u> forms are submitted.																				

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19, 2007

Signature:  (John Barretto)

PC/MS-DOS PATENTIN 3.3
WU, TZZY-CHOOU et al.
Appl. No.: 10/555,669
Filed: 05-MAY-2004
Data Rec: 15-FEB-2007
Atty. Dkt. No: JHV-050.01
(19546-5001)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: JHV-050.01 (19546-5001)

In re patent application of

WU, TZZY-CHOOU et al.

Serial No. 10/555,669

Filed: May 5, 2004

For: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE,
MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Feb. 15, 2007

Date

James A. Coburn

HARBOR CONSULTING IP SERVICES, INC.
1500A Lafayette Road, #262
Portsmouth, N.H. 03801
800-318-3021

SEQUENCE LISTING

<110> WU, TZZY-CHOOU
HUNG, CHIEN, FU

<120> ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

<130> JHV-050.01 (19546-5001)

<140> 10/555,669
<141> 2004-05-05

<150> PCT/US04/013756
<151> 2004-05-05

<150> 60/467,602
<151> 2003-05-05

<160> 20

<170> PatentIn Ver. 3.3

<210> 1
<211> 297
<212> DNA
<213> Human papillomavirus

<220>
<221> CDS
<222> (1)..(297)

<400> 1
atg cat gga gat aca cct aca ttg cat gaa tat atg tta gat ttg caa 48
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15

cca gag aca act gat ctc tac tgt tat gag caa tta aat gac agc tca 96
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30

gag gag gag gat gaa ata gat ggt cca gct gga caa gca gaa ccg gac 144
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45

aga gcc cat tac aat att gta acc ttt tgt tgc aag tgt gac tct acg 192
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60

ctt cgg ttg tgc gta caa agc aca cac gta gac att cgt act ttg gaa 240
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80

gac ctg tta atg ggc aca cta gga att gtg tgc ccc atc tgt tct cag 288
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

gat aag ctt
Asp Lys Leu

297

<210> 2
<211> 99
<212> PRT
<213> Human papillomavirus

<400> 2
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15

Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30

Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45

Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60

Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

Asp Lys Leu

<210> 3
<211> 98
<212> PRT
<213> Human papillomavirus

<400> 3
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15

Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30

Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45

Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60

Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

Lys Pro

<210> 4
 <211> 158
 <212> PRT
 <213> Human papillomavirus

<400> 4
 Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro
 1 5 10 15

Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp
 20 25 30

Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu
 35 40 45

Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly
 50 55 60

Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile
 65 70 75 80

Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu
 85 90 95

Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn
 100 105 110

Cys Gln Lys Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys
 115 120 125

Lys Gln Arg Phe His Asn Ile Arg Gly Arg Trp Thr Gly Arg Cys Met
 130 135 140

Ser Cys Cys Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu
 145 150 155

<210> 5
 <211> 151
 <212> PRT
 <213> Human papillomavirus

<400> 5
 Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys
 1 5 10 15

Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile Leu Glu Cys Val Tyr
 20 25 30

Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe Arg
 35 40 45

Asp Leu Cys Ile Val Tyr Arg Asp Gly Asn Pro Tyr Ala Val Cys Asp
 50 55 60

Lys Cys Leu Lys Phe Tyr Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys
 65 70 75 80

Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu
 85 90 95

Cys Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro Leu Cys Pro
 100 105 110

Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn Ile
 115 120 125

Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys Arg Ser Ser Arg
 130 135 140

Thr Arg Arg Glu Thr Gln Leu
 145 150

<210> 6

<211> 378

<212> DNA

<213> Human papillomavirus

<400> 6

atggcgccgc cggcgcccg cgccgcgcgtg ctccctctgc tgctggcagg ccttgcacat 60
 ggccgcctcag cacttttga ggatccatc atgcatggag atacacccatc attgcatgaa 120
 tatatgttag atttgcaacc agagacaact gatctctact gttatgagca attaaatgac 180
 agctcagagg aggaggatga aatagatgtt ccagctggac aacgcagaacc ggacagagcc 240
 cattaaata ttgttaatctt ttgttgcaag ttgtactcta cgcttcgggtt gtgcgtacaa 300
 agcacacacg tagacattcg tactttgaa gaccgtttaa tgggcacact aggaattgtg 360
 tgcccatct gttctcaa 378

<210> 7

<211> 127

<212> PRT

<213> Human papillomavirus

<400> 7

Met Ala Ala Pro Gly Ala Arg Arg Pro Leu Leu Leu Leu Leu Ala
 1 5 10 15

Gly Leu Ala His Gly Ala Ser Ala Leu Phe Glu Asp Leu Ile Met His
 20 25 30

Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu
 35 40 45

Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser Glu Glu
 50 55 60

Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp Arg Ala
 65 70 75 80

His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr Leu Arg
 85 90 95

Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu Asp Leu
 100 105 110

Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Pro
 115 120 125

<210> 8
 <211> 90
 <212> DNA
 <213> Human papillomavirus

<400> 8
 atggcggccc cggccgcggc gggccgcgtg ctccctgtgc tgctggcagg ccttgcacat 60
 ggcgcctcag cactcttga ggtatctaattc 90

<210> 9
 <211> 1878
 <212> DNA
 <213> Mycobacterium tuberculosis

<400> 9
 atggctcggt cggtcgggat cgacactcggg accaccaact ccgtcgctc gtttctggaa 60
 ggtgcgcacc cggtcgctgt cgccaactcc gagggctcca ggaccacccc gtcattgtc 120
 gcttcgcgc gcaacggtaa ggtgtgtgc gggcagccgg ccaagaacca ggcagtgacc 180
 aaatcgatgc gacccgtcgct ctcggtaaag ccacacatgg ggcgcgactg gtccatagag 240
 attgacgcga aaaaatacac cgcggccggag atacgcgcgc gcattctgtat gaatgtcgaag 300
 cgcgacccgcg aggccatccgt cggtggaggac attacccgac ccgttatacc gacgcggcc 360
 tacttcaatgc acggcccgacg tcaggccacc aaggacgcgcg gccagatgcg cggctcaac 420
 gtgtcggtcg tgcgtacgca gggccggccg ggcgcgtgg cttacggccct cggaaaggc 480
 gagaaggcgc acgcgaatccgttccggac tttgggtgggtgc gacatttcga cgtttccctg 540
 ctggatcgatgc gggagggtgt ggttgagggtc cgttcgcactt cgggtgacaaa ccacccgcgc 600
 ggcgacgact gggaccaggc ggtcgctcgat tggctgggtt acaagttcaa gggcaccaggc 660
 ggcatcgatgc tgaccaaggaa caaatgcgcg atgcacgcgcg tggggaaaggc gggcggaaag 720
 gcaaaatgcg acgtcgatgc ggtcgatcc acctcgatcc acctcgcccta catccaggc 780
 gacgcggacaca aqaaaccggcgttccatggac gaggacgtga cccgcgcggaa gttccaaacgg 840
 atccatcgagg acgttcgtgg cccgcacttcg acggccgttc acgtcggtat cgtcgacacc 900
 ggcatttcgg tgcgtcgaggat cgatcgatgtt gtcgtcggtt gtgttgcgc cccggatgcgc 960
 ggcgttgcgcg atctggtaa ggaatccacc gggccgcggaa aacccaaacaa gggcgtaac 1020
 cccgtatcgatgc ttgtcgcggtt gggagccgtt ctcgcggccg ggcgttccatc gggcgagggt 1080
 aaagacgttc tgctgtttgtt aatcccgatcc ctgacccgtt gatcgagac caaggccggg 1140
 gtgtatcgatcc ggtcgatcc ggcacaaacc acgtatccccc ccaaggccgtt ggagactttc 1200
 accacccgcgc acggacaaacca acggccgtgtt cttatcgagg gggcggttgcg 1260
 atcgccgcgc acaacaaggat gtcgggttcc ttgcgtatccg cccgcaccc gccggccgc 1320
 cgggggatcc cgcacatcgaa ggtcaacttcc gacatcgacg ccaacggcat tggtaacgtc 1380
 accggccaaagg acaaggccac cggcaaggag aacacatccatc gatccaggaa aggtcgccgc 1440
 ctgttcaagg aagacattga ccgcattgtatcc aaggacgcgcg aacgcgcacgc cggaggaggat 1500
 cgcacggatcc gggaggaggc gatgttccatc aatcaaggcc acgatccgtt ctacccaggc 1560
 gagaaggatcc tcaaaacaca ggtgtggcc gagggtgtt cggaggatcc tggaaacacgc 1620
 ctgaaacaaagg ttgtcgccgc ggtggccggaa ggcggccggg cacttggccg atccggatatt 1680
 tggccatcaatc agtcggcgat gggaaactgtt ggcggaggat cgcggatctt ggggcaagcg 1740
 atctacaaagg acgtcgatcc tgcgtccatc gggacttggcc ctggccatcc cggccggcc 1800
 cggggccgtt cccacccccc ctcggatccatc gacgttggcc acgcggaggat ggtcgacgc 1860
 ggcggggagg ccaatgtatcc 1878

<210> 10
 <211> 625
 <212> PRT
 <213> Mycobacterium tuberculosis

<400> 10
 Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser Val Val
 1 5 10 15

Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser Glu Gly
 20 25 30

Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly Glu Val
 35 40 45

Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val Asp Arg
 50 55 60

Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser Ile Glu
 65 70 75 80

Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg Ile Leu
 85 90 95

Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp Ile Thr
 100 105 110

Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln
 115 120 125

Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu Arg Ile
 130 135 140

Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp Lys Gly
 145 150 155 160

Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe
 165 170 175

Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val Arg Ala
 180 185 190

Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln Arg Val
 195 200 205

Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile Asp Leu
 210 215 220

Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala Glu Lys
 225 230 235 240

Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn Leu Pro
 245 250 255

Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp Glu Gln
 260 265 270

Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu Asp Arg
 275 280 285
 Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile Ser Val
 290 295 300
 Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg Met Pro
 305 310 315 320
 Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu Pro Asn
 325 330 335
 Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala Leu Gln
 340 345 350
 Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu Asp Val
 355 360 365
 Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met Thr Arg
 370 375 380
 Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu Thr Phe
 385 390 395 400
 Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val Tyr Gln
 405 410 415
 Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser Phe Glu
 420 425 430
 Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile Glu Val
 435 440 445
 Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala Lys Asp
 450 455 460
 Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly Ser Gly
 465 470 475 480
 Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu Ala His
 485 490 495
 Ala Glu Glu Asp Arg Lys Arg Arg Glu Glu Ala Asp Val Arg Asn Gln
 500 505 510
 Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu Gln Arg
 515 520 525
 Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn Lys Val
 530 535 540
 Asp Ala Ala Val Ala Glu Ala Lys Ala Leu Gly Gly Ser Asp Ile
 545 550 555 560
 Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser Gln Ala
 565 570 575

Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln Ala Thr
 580 585 590

Gly Ala Ala His Pro Gly Gly Glu Pro Gly Gly Ala His Pro Gly Ser
 595 600 605

Ala Asp Asp Val Val Asp Ala Glu Val Val Asp Asp Gly Arg Glu Ala
 610 615 620

Lys
 625

<210> 11
 <211> 2104
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(2103)

<220>
 <223> Description of Artificial Sequence: Synthetic
 construct

<400> 11
 atg cat gga gat aca cct aca ttg cat gaa tat atg tta gat ttg caa 48
 Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
 1 5 10 15

cca gag aca act gat ctc tac tgt tat gag caa tta aat gac agc tca 96
 Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
 20 25 30

gag gag gag gat gaa ata gat ggt cca gct gga caa gca gaa ccg gac 144
 Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
 35 40 45

aga gcc cat tac aat att gta acc ttt tgt tgc aag tgt gac tct acg 192
 Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
 50 55 60

ctt cgg ttg tgc gta caa agc aca cac gta gac att cgt act ttg gaa 240
 Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
 65 70 75 80

gac ctg tta atg ggc aca cta gga att gtg tgc ccc atc tgt tct caa 288
 Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
 85 90 95

gga tcc atg gct cgt gcg gtc ggg atc gac ctc ggg acc acc aac tcc 336
 Gly Ser Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser
 100 105 110

gtc gtc tcc gtt ctg gaa ggt ggc gac ccg gtc gtc gtc gcc aac tcc 384
 Val Val Ser Val Leu Glu Gly Asp Pro Val Val Ala Asn Ser
 115 120 125

gag ggc tcc agg acc acc ccg tca att gtc gcg ttc gcc cgc aac ggt		432
Glu Gly Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly		
130	135	140
gag gtg ctg gtc ggc cag ccc gcc aag aac cag gca gtg acc aac gtc		480
Glu Val Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val		
145	150	155
160		
gat cgc acc gtg cgc tcg gtc aag cga cac atg ggc agc gac tgg tcc		528
Asp Arg Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser		
165	170	175
ata gag att gac ggc aag aaa tac acc gcg ccg gag atc agc gcc cgc		576
Ile Glu Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg		
180	185	190
att ctg atg aag ctg aag cgc gac gcc gag gcc tac ctc ggt gag gac		624
Ile Leu Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp		
195	200	205
att acc gac gcg gtt atc acg acg ccc gcc tac ttc aat gac gcc cag		672
Ile Thr Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln		
210	215	220
cgt cag gcc acc aag gac gcc ggc cag atc gcc ggc ctc aac gtc ctg		720
Arg Gln Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu		
225	230	235
240		
cggtatcgttacaaacggccaccggccggccctgttacggccctcgttacggccgttac		768
Arg Ile Val Asn Glu Pro Thr Ala Ala Leu Ala Tyr Gly Leu Asp		
245	250	255
aag ggc gag aag gag cag cga atc ctg gtc ttc gac ttg ggt ggt ggc		816
Lys Gly Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly		
260	265	270
act ttc gag gtt tcc ctg ctg gag atc ggc gag ggt gtc gtt gag gtc		864
Thr Phe Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val		
275	280	285
cgt gcc act tcg ggt gac aac cac ctc ggc ggc gac gac tgg gac cag		912
Arg Ala Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln		
290	295	300
cggtatcgttacaaacggccaccggccggccctgttacggccctcgttacggccgttac		960
Arg Val Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile		
305	310	315
320		
gat ctg acc aag gac aag atg gcg atg cag cgg ctg cgg gaa gcc gcc		1008
Asp Leu Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala		
325	330	335
gag aag gca aag atc gag ctg agt tcg agt cag tcc acc tcg atc aac		1056
Glu Lys Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn		
340	345	350

ctg ccc tac atc acc gtc gac gcc gac aag aac ccg ttg ttc tta gac Leu Pro Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp 355	360	365	1104	
gag cag ctg acc cgc gcg gag ttc caa ccg atc act cag gag ctg ctg Glu Gln Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu 370	375	380	1152	
gac cgc act cgc aag ccg ttc cag tcg gtg atc gct gac acc ggc att Asp Arg Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile 385	390	395	400	1200
tcg gtg tcg gag atc gat cac gtt gtg ctc gtg ggt ggt tcg acc cgg Ser Val Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg 405	410	415	1248	
atg ccc gcg gtg acc gat ctg gtc aag gaa ctc acc ggc ggc aag gaa Met Pro Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu 420	425	430	1296	
ccc aac aag ggc gtc aac ccc gat gag gat gtc gcg gtg gga gcc gct Pro Asn Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala 435	440	445	1344	
ctg cag gcc gtc ctc aag ggc gag gtg aaa gac gtt ctg ctg ctt Leu Gln Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu 450	455	460	1392	
gat gtt acc cog ctg agc ctg ggt atc gag acc aag ggc ggg gtg atg Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met 465	470	475	480	1440
acc agg ctc atc gag cgc aac acc acg atc ccc acc aag cgg tcg gag Thr Arg Leu Ile Glu Arg Asn Thr Ile Pro Thr Lys Arg Ser Glu 485	490	495	1488	
act ttc acc acc gcc gac gac aac caa ccg tcg gtg cag atc cag gtc Thr Phe Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val 500	505	510	1536	
tat cag ggg gag cgt gag atc gcc gcg cac aac aag ttg ctc ggg tcc Tyr Gln Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser 515	520	525	1584	
ttc gag ctg acc ggc atc ccg ccg gcg ccg cgg ggg att ccg cag atc Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile 530	535	540	1632	
gag gtc act ttc gag atc gag gcc aac ggc att gtg cac gtc acc gcc Glu Val Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala 545	550	555	560	1680
aag gac aag ggc acc ggc aag gag aac acg atc cga atc cag gaa ggc Lys Asp Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly 565	570	575	1728	

tcg ggc ctg tcc aag gaa gac att gac cgc atg atc aag gac gcc gaa	1776
Ser Gly Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu	
580 585 590	
gcg cac gcc gag gag gat cgc aag cgt cgc gag gag gcc gat gtt cgt	1824
Ala His Ala Glu Glu Asp Arg Lys Arg Arg Glu Ala Asp Val Arg	
595 600 605	
aat caa gcc gag aca ttg gtc tac cag acg gag aag ttc gtc aaa gaa	1872
Asn Gln Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu	
610 615 620	
cag cgt gag gcc gag ggt ggt tcg aag gta cct gaa gac acg ctg aac	1920
Gln Arg Glu Ala Glu Gly Ser Lys Val Pro Glu Asp Thr Leu Asn	
625 630 635 640	
aag gtt gat gcc gcg gtg gcg gaa gcg aag gcg gca ctt ggc gga tcg	1968
Lys Val Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Gly Ser	
645 650 655	
gat att tcg gcc atc aag tcg gcg atg gag aag ctg ggc cag gag tcg	2016
Asp Ile Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser	
660 665 670	
cag gct ctg ggg caa gcg atc tac gaa gca gct cag gct gcg tca cag	2064
Gln Ala Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln	
675 680 685	
gcc act ggc gct gcc cac ccc ggc tcg gct gat gaa agc a	2104
Ala Thr Gly Ala Ala His Pro Gly Ser Ala Asp Glu Ser	
690 695 700	

<210> 12
 <211> 701
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 construct

<400> 12	
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln	
1 5 10 15	
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser	
20 25 30	
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp	
35 40 45	
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr	
50 55 60	
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu	
65 70 75 80	

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
 85 90 95
 Gly Ser Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser
 100 105 110
 Val Val Ser Val Leu Glu Gly Gly Asp Pro Val Val Ala Asn Ser
 115 120 125
 Glu Gly Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly
 130 135 140
 Glu Val Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val
 145 150 155 160
 Asp Arg Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser
 165 170 175
 Ile Glu Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg
 180 185 190
 Ile Leu Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp
 195 200 205
 Ile Thr Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln
 210 215 220
 Arg Gln Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu
 225 230 235 240
 Arg Ile Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp
 245 250 255
 Lys Gly Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly
 260 265 270
 Thr Phe Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val
 275 280 285
 Arg Ala Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln
 290 295 300
 Arg Val Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile
 305 310 315 320
 Asp Leu Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala
 325 330 335
 Glu Lys Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn
 340 345 350
 Leu Pro Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp
 355 360 365
 Glu Gln Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu
 370 375 380

Asp Arg Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile
 385 390 395 400

Ser Val Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg
 405 410 415

Met Pro Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu
 420 425 430

Pro Asn Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala
 435 440 445

Leu Gln Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu
 450 / 455 460

Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met
 465 470 475 480

Thr Arg Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu
 485 490 495

Thr Phe Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val
 500 505 510

Tyr Gln Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser
 515 520 525

Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile
 530 535 540

Glu Val Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala
 545 550 555 560

Lys Asp Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly
 565 570 575

Ser Gly Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu
 580 585 590

Ala His Ala Glu Glu Asp Arg Lys Arg Arg Glu Glu Ala Asp Val Arg
 595 600 605

Asn Gln Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu
 610 615 620

Gln Arg Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn
 625 630 635 640

Lys Val Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Ser
 645 650 655

Asp Ile Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser
 660 665 670

Gln Ala Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln
 675 680 685

Ala Thr Gly Ala Ala His Pro Gly Ser Ala Asp Glu Ser
690 695 700

<210> 13
<211> 6681
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
vector

aaatagggggt tccgcgcaca ttccccggaa aagtgcacc tgacgttaa gaaaccatt 2640
ttatcatgcat attacaataaa aaaaataggc tccatcaggc ggcccttgc ctggcgctt 2700
tcgggtatgtc cgggtaaaaaa ctgcacacaa tgcaatccgc ggagacggctc acagctgtc 2760
tgaagcgggta tgccggggage agacaagccc gtcaaggcgc gtacggcgtt gttggcggtt 2820
ggcgggggtt gcttaactat gggccatgtc agcagatgtt actggatgtt caccatcgc 2880
gggtgtaaat caccgcacaa tgcgtaaaggaa gaaaataccatc catcaggatg gatattggcc 2940
attgcatacg ttgtatccatc atcataatat gtacattat tattgtctt atgcattat tgcacacat 3000
acccgcattgt tgacattatc tattgtactg tttataatag taatcaatta cgggtttcatc 3060
aggctatagc cccatataatgg agtcccggt tacataactt acggttaatgg gccccttgg 3120
otgacccccc aaccggcccccc gcccaatggcgtt gtcataatagt acgtatgtt cttatcgtt 3180
gccaataggg atttccttc gacgtcaatgg gttggatgtt tttatggtaaaatc cttcccaactt 3240
ggcgcgtatcatc caagtgtatc atatgccaag tagccccctt attgacgtca ataggcgatc 3300
attggccccc tggccattatgg ccacgtatcatc gacgtttatgg gactttctt cttggatgtt 3360
catctatcgta ttagatcgatc attatccatc gtttgcattatgg tttttgcgtt acatcaatgg 3420
ggcgttgcata ggggtttgtt cggccggattt tccaagtttc ccccccattgt acgttgcattt 3480
gagggtttttt tggccacaaaat aacccggaaat cttcccaaaaat tttatggatc acccggcccc 3540
attgcacatc atggccgtta ggcgttgcgtt gttggggatgtt tttatggatc acggctgtt 3600
agtacacgtt cagatgcgtt gggagacgcata tccacgttgc tttttatggatc ataaagacca 3660
ccggggatcga tccaggcttc gggccggggaa acgggtttatgg gaaacggggaa tttcccggtt 3720
caagatgtac gtaatgttccctt cttatagatc ctataggcactt acccctttgg ctctttatgc 3780
tgctatatact tttttttttttt gggccctataaa ccccccgtt ctccatgtt atgttgcgtt 3840
gtatagcttca gtcattatgtt gttttttttt gggccattttt gacccatccaa acgggtgggg 3900
ggactgttgcgtt ctgagcgtttt tttttttttt gggccattttt gacccatccaa acgggtgggg 3960
actacaaacatc atgttgcctt tttttttttt gggccattttt gacccatccaa acgggtgggg 4020
gataatgttgc atatgcataatc tttttttttt gggccattttt gacccatccaa acgggtgggg 4080
gctgtcttgc ctgctgttgc cggccgttgc acatggccgc tcacgtactt ttggatgtt 4140
aatcatgtatc gggatataccatc ctatattgcata tttttttttt gggccattttt gacccatccaa 4200
actgtatccctc tttttttttt gggccattttt gacccatccaa acgggtgggg 4260
tggttccatgtt ggcacacggatc aaccggccatc acggccatccaa atatttgatc cttttttttt 4320
caatgtgtac tttttttttt gggccattttt gacccatccaa acgggtgggg 4380
ggaaagatctt tttttttttt gggccattttt gacccatccaa acgggtgggg 4440
ggctgttgcgtt gttttttttt gggccattttt gacccatccaa acgggtgggg 4500
ttggccacccg tttttttttt gggccattttt gacccatccaa acgggtgggg 4560
gttgcggccgc aacgggttggg tttttttttt gggccattttt gacccatccaa acgggtgggg 4620
ctgtcgtatgc acggctgttgc tttttttttt gggccattttt gacccatccaa acgggtgggg 4680
tgcacggcggaa ataaatccatc cggccggatgtt tttttttttt gggccattttt gacccatccaa 4740
cgacggcccgatc gttttttttt gggccattttt gacccatccaa acgggtgggg 4800
cttcaatgtatc gccacatccatc tttttttttt gggccattttt gacccatccaa acgggtgggg 4860
gttgcggatc gttttttttt gggccattttt gacccatccaa acgggtgggg 4920
gaaggagacgc gcaatcttgc tttttttttt gggccattttt gacccatccaa acgggtgggg 4980
ggagatcgccg ggggtttttt gggccattttt gacccatccaa acgggtgggg 5040
cgacgacttgc gaccaggccgg tttttttttt gggccattttt gacccatccaa acgggtgggg 5100
catcgatcttcc accaaaggatc agatgttgcgtt gggccattttt gacccatccaa acgggtgggg 5160
aaataggatcgatc ttgtatgttgc tttttttttt gggccattttt gacccatccaa acgggtgggg 5220
cgccgacaaatc aaccctgttgc tttttttttt gggccattttt gacccatccaa acgggtgggg 5280
cactcaggatc ctgtgttgcacc gacacttgc tttttttttt gggccattttt gacccatccaa 5340
cattttgtgttcc tggatgtatc acatcgatgtt gttttttttt gggccattttt gacccatccaa 5400
gggtgcgtatc ttgtatgttgc aacttcacccgg tttttttttt gggccattttt gacccatccaa 5460
cgatgttgcgtt gttttttttt gggccattttt gacccatccaa acgggtgggg 5520
aaatggcttgc tttttttttt gggccattttt gacccatccaa acgggtgggg 5580
gtatgttgcgtt gttttttttt gggccattttt gacccatccaa acgggtgggg 5640
caccatcgatc gttttttttt gggccattttt gacccatccaa acgggtgggg 5700
cgccggccgcac gacaacaaatc cttttttttt gggccattttt gacccatccaa acgggtgggg 5760
ggggatcttgc cagatgttgcgtt tttttttttt gggccattttt gacccatccaa acgggtgggg 5820
cgccaaacggatc aagggttgcgtt gttttttttt gggccattttt gacccatccaa acgggtgggg 5880
gttcaaggaa gacattgttgc gatgtatcaatc gttttttttt gggccattttt gacccatccaa acgggtgggg 5940
caacggcttgc gaggatgttgcgtt atgttgcgtt tttttttttt gggccattttt gacccatccaa 6000
gaagtctgttccaa aagaacatgttgcgtt gttttttttt gggccattttt gacccatccaa acgggtgggg 6060

gaacaagggtt gatgccgggg tggcggaaagc gaaggccgcg cttggcgatc cggatatttc 6120
 ggccatcaag tcggcgatgg agaagctggg ccaggaggatcg caggctctgg ggcaagcgat 6180
 ctacaaggca gctcaggctt cgtcacaggc cactggcgct gccccccccc gtcggctga 6240
 tggaaaggcta agttttaaacc gctagccctag acggggcccg gatccagatc tttttccctc 6300
 tgccaaaaat tatggggaca tcatgaaggcc ctttgagcat ctgacttctgg gctaataaag 6360
 gaaattttat ttcatggcaa tagtggttg gaaattttttg tgctcttcaac tccgaaggac 6420
 atatggggagg gcaaatcatt taaaacatca gaatgagttt ttgggtttaga gttggcaac 6480
 atatggccat tcttccggctt cctcgctcac tgactcgctg cgctcggtcg ttccggctcg 6540
 gcgagcggta tcagtcactt caaaggcggtt aatacggtt tccacagataa cagggatataa 6600
 cgcgaggaaag aacatgtgag caaaaggccca gcaaaaaggcc aggaaccgtt aaaaaggccgc 6660
 gttgtggc ttttccata g 6681

<210> 14
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 14
 ctgatctcta cggttatggg caattaaatg acagctc 37

<210> 15
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<400> 15
 gagctgtcat ttaattgccc ataaccgtag agatca 36

<210> 16
 <211> 9
 <212> PRT
 <213> Human papillomavirus

<400> 16
 Arg Ala His Tyr Asn Ile Val Thr Phe
 1 5

<210> 17
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (1)..(21)

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 17
ctc tac tgt tat gag caa tta
Leu Tyr Cys Tyr Glu Gln Leu
1 5

21

<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 18
Leu Tyr Cys Tyr Glu Gln Leu
1 5

<210> 19
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(21)

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19
ctc tac ggt tat ggg caa tta
Leu Tyr Gly Tyr Gly Gln Leu
1 5

21

<210> 20
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 20
Leu Tyr Gly Tyr Gly Gln Leu
1 5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouo *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.



John Barreto

PRELIMINARY AMENDMENT

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Prior to substantive examination of the above-referenced patent application, please amend the application as follows:

Amendments to the specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on page 8, line 13 with the following amended paragraph:

Figure 5A is a schematic diagram of the pNGVL4a-Sig/E7 (detox) /HSP70 plasmid vector used for anti-tumor vaccination. Indicated are various inserts and p Fig. 5B discloses SEQ ID NOS: 17-20, respectively, in order of appearance.

Please replace the paragraph beginning on page 34, line 6 with the following amended paragraph:

A portion of SEQ ID NO: 13 above vector showing by annotation annotated with the Sig, E7 (detox) and HSP-70 regions is shown below (nucleotides 3951-6350 of SEQ ID NO: 13). The vector sequence is in lower case; the signal peptide (Sig) is bold italic and annotated over the lines. The E7 (detox) sequence is upper case underscored (and annotated over the lines). The HSP70 sequence is italicized and underscored[[.]] (not bolded) and is also annotated over the lines.

REMARKS


The foregoing amendments have been made to correct typographical errors and to insert the required SEQ ID NO identifiers associated with various listed sequences. No new matter has been added.

CONCLUSION

Applicants respectfully request entry of the present Preliminary Amendment. Early and favorable consideration of the application is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at (617) 832-1000. The Commissioner is hereby authorized to charge any necessary fees to our **Deposit Order Account No. 06-1448, reference JHV-050.01.**

Respectfully submitted,
FOLEY HOAG

Dated: March 19, 2007
Customer Number 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600
Tel: (617) 832-1000
FAX: (617) 832-7000



Janann Y. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicant

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN	
As the below named inventor(s), I/we declare that:	
This declaration is directed to:	
<input type="checkbox"/> The attached application, or <input checked="" type="checkbox"/> Application No. PCT/US04/13756, filed on 05/05/2004, <input checked="" type="checkbox"/> as amended on 11/07/2005 (if applicable);	
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;	
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.	
WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.	
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	

FULL NAME OF INVENTOR(S)

Inventor one: Tzyy-Chou Wu

Signature:  Citizen of: U.S.A.

Inventor two: Chien-Fu Hung

Signature:  Citizen of: Taiwan

Inventor three:

Signature: Citizen of:

Inventor four:

Signature: Citizen of:

Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number		10/555,669-Conf. #9879
Filing Date		May 5, 2004
First Named Inventor		Tzyy-Chou Wu
Title	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN	
Art Unit	N/A	
Examiner Name	Not Yet Assigned	
Attorney Docket No.	JHV-050.01	

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

Practitioners associated with the Customer Number:

OR

Practitioner(s) named below:

Name	Registration Number	Name	Registration Number
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number:

OR

The address associated with Customer Number:

OR

Firm or
Individual Name

Address City State Zip Country Telephone Email


I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature Date Name Telephone Title and Company

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of forms are submitted.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10/555,669-Conf. #9879
Filing Date	May 5, 2004
First Named Inventor	Tzyy-Chou Wu
Title	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket No.	JHV-050.01

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

Practitioners associated with the Customer Number:

OR

Practitioner(s) named below:

Name	Registration Number	Name	Registration Number
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number:

OR

The address associated with Customer Number:

OR

Firm or
Individual Name

Address City State Zip Country Telephone Email

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Chien-Fu Hung</i>	Date	<i>2/21/07</i>
Name	Chien-Fu Hung	Telephone	<i>410-502-8215</i>
Title and Company	Inventor		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

*Total of 2 forms are submitted.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouo *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barreto

NOTIFICATION OF CHANGE OF ATTORNEY DOCKET NUMBER

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Attorney Docket Number of the above-identified patent application has changed. Please take notice that the *correct* Attorney Docket Number for this application should now be as follows:


JHV-050.01

Please reference **JHV-050.01** on all future correspondence to the attorney of record.

Respectfully Submitted,

Date: March 19, 2007

Customer No: 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600


Janann Ali, Ph.D.
Reg. No. 54,958
Agent for Applicants
Tel. (617) 832-1000
Fax. (617) 832-7000